Page last updated: 2024-11-11

hr 810

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cefpirome: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cefpirome : A fourth-generation cephalosporin antibiotic having 6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5479539
CHEMBL ID65794
CHEBI ID3503
SCHEMBL ID49406
SCHEMBL ID22207951
MeSH IDM0116916

Synonyms (44)

Synonym
keiten
hr-810
broact
D07649
cefir (tn)
cefpirome (inn)
84957-29-9
hr 810
cefpirome
cefpiromum [latin]
1-(((6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-6,7-dihydro-5h-1-pyridinium hydroxide, inner salt
cefpiroma [spanish]
cefpirome [inn:ban]
5h-1-pyrindinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-6,7-dihydro-, hydroxide, inner salt, (6r-(6alpha,7beta(z)))-
5h-1-pyrindinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-5,6,7,8-tetrahydro-, hydroxide, inner salt, (6r-(6alpha,7beta(z)))-
chebi:3503 ,
cefir
hr-810 free base
CHEMBL65794
(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5h-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
cefpiromum
cefpiroma
(6r,7r)-7-((2-(2-amino-4-thiazolyl)-2-methoxyiminoacetamido)-8-oxo-3-(2beta-trimethylenpyridinio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carboxylat
unii-s72q2f09hy
s72q2f09hy ,
AKOS016013926
cefpirome [inn]
5h-1-pyrindinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-6,7-dihydro-, hydroxide, inner salt, (6r-(6.alpha.,7.beta.(z)))-
cefpirome [who-dd]
cefpirome [mi]
1-(((6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-6,7-dihydro-5h-1-pyrindinium hydroxide, inner salt, 72-(z)-(o-methyloxime)
SCHEMBL49406
MLS006010792
smr004701476
DTXSID2048244
7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-(6,7-dihydro-5h-cyclopenta[b]pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylic acid
(6r,7r)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-(6,7-dihydro-5h-cyclopenta[b]pyridinium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-{[(6r,7r)-2-carboxylato-7-{[(2z)-1-hydroxy-2-(2-imino-2,3-dihydro-1,3-thiazol-4-yl)-2-(methoxyimino)ethylidene]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-5h,6h,7h-cyclopenta[b]pyridin-1-ium
DB13682
5h-cyclopenta[b]pyridinium,1-[[(6r,7r)-7-[[(2z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-6,7-dihydro-, inner salt
SCHEMBL22207951
keiten, cefpiroma
1-{[(6r,7r)-7-[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-5h,6h,7h-cyclopenta[b]pyridin-1-ium
EN300-24767392

Research Excerpts

Overview

HR 810 or cefpirome is a new 2-amino-thiazol cephalosporin. Its specific characteristic is a cyclopentenopyridinium group in position 3 of the cephem nucleus.

ExcerptReferenceRelevance
"HR 810 or cefpirome is a new 2-amino-thiazol cephalosporin whose salient characteristic is a bicyclic nucleus, namely cyclopenteno-pyridinium, in position 3. "( [Cefpirome (HR 810). A new broad spectrum cephalosporin].
Bryskier, A; Chantot, JF, 1985
)
2.09
"HR 810 or cefpirome is a new amino thiazole cephalosporin whose specific characteristic is a cyclopentenopyridinium group in position 3 of the cephem nucleus. "( [HR 810 (cefpirome). Experimental evaluation of the in vitro and in vivo antibiotic activity of a new amino-2-thiazole methoxy- imino cephalosporin].
Bryskier, A; Chantot, JF, 1985
)
2.62

Toxicity

ExcerptReferenceRelevance
" The LD50 values of CPR (mg/kg) were as follows: (1) mice: intravenous, 2420 (95% confidence limits, 2122-2758) for males and 2400 (2181-2640) for females; intraperitoneal, 3850 (3407-4351) for males and 4200 (3889-4536) for females; and oral, 16200 (14781-17755) for males and 18500 (17290-19795) for females."( [Acute toxicity study of cefpirome sulfate in mice and rats].
Abe, S; Inazu, M; Kobayashi, T; Omosu, M; Oshima, K; Satoh, R; Wada, N, 1990
)
0.28
" The drug was safe and well tolerated."( Safety, tolerance and pharmacokinetics of 2.0 g cefpirome (HR 810) after single and multiple dosing.
Badian, M; Collins, JD; Dixon, GT; Eckert, HG; Malerczyk, V; Verho, M, 1988
)
0.52
" Adverse effects, probably or possibly related to cefpirome, were skin reactions (3), fever (1), Clostridium difficile diarrhoea (2), and disturbed taste sensation (1)."( Efficacy and safety of cefpirome (HR810).
Alestig, K; Burman, LA; Dotevall, L; Eriksson, M; Larsson, P; Lundholm, R; Norrby, SR; Settergren, B, 1988
)
0.27
" The overall incidence of clinical adverse events with cefpirome was 21."( A review of the adverse events profile of cefpirome.
Labs, R; Reeves, A; Rubinstein, E, 1993
)
0.29
" Cefpirome did not differ from comparators in terms of frequencies or distribution within body systems of adverse events."( Cefpirome: efficacy in the treatment of urinary and respiratory tract infections and safety profile.
Norrby, SR, 1993
)
0.29
" Similar adverse events, including rashes, gastrointestinal upset and asymptomatic elevation of hepatic enzymes, occurred in a minority of patients in both groups."( Safety and efficacy of cefpirome in comparison with ceftazidime in Chinese patients with sepsis due to bacterial infections.
Chang, SC; Chen, YC; Fang, CT; Lin, SF; Liu, CJ; Shau, WY; Sheng, WH; Wang, JT,
)
0.13
"CPM is as safe and effective as ceftazidime in the treatment of sepsis due to bacterial infections in Chinese patients."( Safety and efficacy of cefpirome in comparison with ceftazidime in Chinese patients with sepsis due to bacterial infections.
Chang, SC; Chen, YC; Fang, CT; Lin, SF; Liu, CJ; Shau, WY; Sheng, WH; Wang, JT,
)
0.13

Pharmacokinetics

Cefpirome (HR 810) is an aminothiazolylmethoxyiminoacetamido cephalosporin (ATOIC) The pharmacokinetic profile of HR 810 was investigated in mice, rats, rabbits, dogs and monkeys.

ExcerptReferenceRelevance
"The pharmacokinetic properties of SCE-2787 administered intravenously at a dose of 20 mg/kg of body weight were studied with mice, rats, rabbits, dogs, and monkeys and were compared with those of ceftazidime, cefpirome, and cefclidin in mice and dogs."( Comparative pharmacokinetics of SCE-2787 and related antibiotics in experimental animals.
Imada, A; Kita, Y; Yamazaki, T, 1992
)
0.28
" The pharmacokinetic parameters were calculated using a two-compartment model."( Single- and multiple-dose pharmacokinetics of intravenous cefpirome (HR810) to healthy volunteers.
Akieda, Y; Imamura, N; Katagiri, K; Nakayama, I; Nitta, Y; Ohishi, M; Takase, K; Yamaji, E, 1992
)
0.28
"The pharmacokinetic profile of cefpirome was evaluated in rats and dogs after a single intravenous or intramuscular dose."( Pharmacokinetics of cefpirome administered intravenously or intramuscularly to rats and dogs.
Isert, D; Klesel, N; Limbert, M; Markus, A; Schrinner, E; Seibert, G, 1992
)
0.28
" The terminal half-life (2 h) was not influenced by dose or duration of dosing."( Safety, tolerance and pharmacokinetics of cefpirome administered intramuscularly to healthy subjects.
Badian, M; Drees, B; Eckert, HG; Luus, HG; Meyer, BH; Muller, FO; Röthig, HJ, 1992
)
0.28
"The pharmacokinetic parameters of cefpirome (HR 810) were examined in 22 patients with different degrees of renal impairment."( Single-dose pharmacokinetics of cefpirome in patients with renal impairment.
Drees, B; Lameire, N; Lehr, K; Malerczyk, V; Rosenkranz, B, 1992
)
0.54
" The pharmacokinetic analyses were based on a two compartment open model."( [Pharmacokinetics of cefpirome (CPR) in patients with impaired renal function].
Ogata, Y; Saruta, T; Suzuki, H, 1991
)
0.28
"Bacteriological, pharmacokinetic and clinical studies on cefpirome (CPR, HR 810), a new cephem antibiotic, were carried out in the field of pediatrics."( [Bacteriological, pharmacokinetic and clinical studies of cefpirome in the field of pediatrics].
Andou, H; Kito, O; Kuno, K; Ogawa, A; Takeuchi, H; Takimoto, Y; Tomita, K, 1991
)
0.51
" After 30- and 60-minute intravenous drip infusions at the same dose, the pharmacokinetic parameters observed were similar to those obtained with one shot injections."( [Bacteriological, pharmacokinetic and clinical evaluations of cefpirome sulfate in the pediatric field. Pediatric Study Group of Cefpirome].
Abe, T; Fujii, R; Hirama, Y; Matsumoto, K; Meguro, H; Nakazawa, S; Narita, A; Sato, H; Tajima, T, 1991
)
0.28
"We conducted a pharmacokinetic and clinical study on cefpirome (HR 810, CPR), an aminothiazolylmethoxyiminoacetamido cephalosporin (ATOIC), and obtained the following results."( [Pharmacokinetic and clinical evaluation of cefpirome in the pediatric field].
Kawamura, K; Sakaguchi, N; Seo, K; Sugita, M; Toyonaga, Y; Yamori, K, 1991
)
0.52
"This study describes the pharmacokinetic characteristics and clinical usefulness of cefpirome (CPR) in children."( [Pharmacokinetical and clinical study of cefpirome in children].
Kida, K; Matsuda, H; Morimoto, T; Murase, M, 1991
)
0.28
"93) and was used to quantitate the concentration of HR 810 in rabbit plasma and determine its half-life subsequent to a 20-mg/kg intramuscular dose."( High-pressure liquid chromatographic assay and pharmacokinetics of HR 810 after intramuscular injection in rabbits.
Bawdon, RE; Brater, DC; Lu, YS, 1985
)
0.76
"The pharmacokinetic profile of HR 810 was investigated in mice, rats, rabbits, dogs and monkeys."( Pharmacokinetic properties of the new cephalosporin antibiotic HR 810 in animals.
Klesel, N; Seeger, K,
)
0.66
" The pharmacokinetic properties of cefpirome are typical of cephalosporins."( Cefpirome clinical pharmacokinetics.
Nix, DE; Strenkoski, LC, 1993
)
0.29
" These pharmacodynamic characteristics suggest that the goal of optimal dosing regimens for cefpirome is to provide serum levels above the MIC of infecting pathogens for most of the dosing interval."( The pharmacokinetics of cefpirome--rationale for a twelve-hour dosing regimen.
Craig, WA, 1993
)
0.29
" In conclusion, this chronic model of catheterized micropig is suitable for long term pharmacokinetic and pharmacodynamic investigations of antiinfective agents."( [Model of a miniature pig catheterized for pharmacokinetic and pharmacodynamic studies of anti-infective agents].
Cavalier, A; Elkhaïli, H; Jehl, F; Kaltenbach, G; Levêque, D; Monteil, H; Peter, JD; Salmon, J; Salmon, Y, 1996
)
0.29
" The pharmacokinetic parameters were studied in 10 patients with end-stage renal disease who were receiving hemodialysis."( Multiple-dose pharmacokinetics of cefpirome in long-term hemodialysis with high-flux membranes.
Atteneder, M; Breyer, S; Burgmann, H; Elmenyawi, I; Georgopoulos, A; Graninger, W; Hollenstein, U; Hörl, WH; Mayer, G; Putz, D; Rosenkranz, AR; Schmaldienst, S; Thalhammer, F, 1996
)
0.29
"To determine the pharmacokinetic parameters of cefpirome, a new so-called fourth-generation cephalosporin, in previously healthy trauma patients with posttraumatic systemic inflammatory response syndrome (SIRS) and to compare them to parameters obtained in matched, healthy volunteers."( Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome.
Edouard, AR; Incagnoli, P; Jacolot, A; Mimoz, O; Petitjean, O; Samii, K; Tod, M, 1999
)
0.3
"Antibiotic concentrations in plasma were measured by high-performance liquid chromatography; their pharmacokinetic parameters were evaluated at 12 time points after the first drug administration using a noncompartmental model."( Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome.
Edouard, AR; Incagnoli, P; Jacolot, A; Mimoz, O; Petitjean, O; Samii, K; Tod, M, 1999
)
0.3
"No major pharmacokinetic modification was noted when cefpirome was given to trauma patients with posttraumatic SIRS without significant organ failure, indicating that no dosage adjustment seems required in this population."( Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome.
Edouard, AR; Incagnoli, P; Jacolot, A; Mimoz, O; Petitjean, O; Samii, K; Tod, M, 1999
)
0.3
"On the basis of previously published pharmacodynamic characteristics of cefpirome and the pharmacokinetic parameters obtained in this study, we calculated a required total daily dose of 2 g every 8 hours to achieve sufficient plasma antibiotic levels to cover the majority of target pathogens."( Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval.
Banyai, M; El-Menyawi, I; Heinz, G; Siostrzonek, P; Thalhammer, F; Traunmüller, F, 2000
)
0.31
" To use the pharmacokinetic model to simulate alternate dosing regimens and identify those that predict sustained levels."( Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing.
Fraenkel, D; Lipman, J; Rickard, CM; Wallis, SC, 2001
)
0.31
" Pharmacokinetic simulation predicted that more frequent bolus dosing, increased doses and continuous infusions would result in concentrations greater than 4 mg/l for over 60% of the dosing interval for all patients."( Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing.
Fraenkel, D; Lipman, J; Rickard, CM; Wallis, SC, 2001
)
0.31
" Thus, cefpirome exhibits a tissue pharmacokinetic profile, which seems to be particularly valuable for the empirical therapy of patients with sepsis."( Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis.
Delle-Karth, G; Heinz, G; Joukhadar, C; Klein, N; Kreischitz, N; Mayer, BX; Müller, M; Palkovits, P, 2002
)
0.31
"The pharmacokinetic profile of antibiotics at the site of antiinfective action is one of the most important determinants of drug response, since it correlates the antimicrobial effect."( [Pharmacokinetics of antibiotics in inflamed and healthy lung tissue].
Maier, A; Smolle-Jüttner, FM; Tomaselli, F, 2003
)
0.32
" Two separate but similar pharmacokinetic studies (which used 2 g twice daily for each antibiotic) were conducted."( Cefepime versus cefpirome: the importance of creatinine clearance.
Boots, RJ; Lipman, J; Wallis, SC, 2003
)
0.32
" To assess the antibacterial effect of cefpirome at the target site, the measured pharmacokinetic profiles were simulated in vitro with select strains of Staphylococcus aureus and Pseudomonas aeruginosa."( Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients.
Delle-Karth, G; Georgopoulos, A; Joukhadar, C; Marsik, C; Mayer-Helm, BX; Müller, M; Sauermann, R; Steiner, I; Zeitlinger, M, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" As pharmacokinetic (PK) data on cefpirome from studies of CF patients are lacking, we systematically compared its population PK and pharmacodynamic breakpoints for CF patients and healthy volunteers of similar body size."( Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.
Bulitta, JB; Holzgrabe, U; Kinzig, M; Landersdorfer, CB; Sörgel, F; Stephan, U, 2011
)
0.37
" Therefore, the pharmacodynamic (PD) parameter of the efficacy of β-lactam antibiotics, that is, the time that its concentration is above the bacteria minimal inhibitory concentration (T > MIC), cannot be safely extrapolated from data derived from the PK of healthy volunteers."( Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J; Póvoa, P, 2011
)
0.37
" Consequently, in ICU patients, β-lactam antibiotic half-life and T > MIC were virtually unpredictable, especially in those patients with normal renal function."( Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J; Póvoa, P, 2011
)
0.37
"We developed a detailed, whole-body physiologically based pharmacokinetic (PBPK) modeling tool for calculating the distribution of pharmaceutical agents in the various tissues and organs of a human or animal as a function of time."( BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems.
Graf, JF; Scholz, BJ; Zavodszky, MI, 2012
)
0.38
" A pharmacokinetic two-stage model was applied."( Abscess penetration of cefpirome: concentrations and simulated pharmacokinetic profiles in pus.
Böhmdorfer, M; Feurstein, T; Jäger, W; Karch, R; Kjellsson, MC; Langenberger, H; Püspök, A; Sauermann, R; Wild, T; Winkler, S; Zeitlinger, M, 2012
)
0.38
"To obtain the optimal dosage regimen in patients receiving extracorporeal membrane oxygenation (ECMO), we developed a population pharmacokinetics model for cefpirome and performed pharmacodynamic analyses."( Dose Optimization of Cefpirome Based on Population Pharmacokinetics and Target Attainment during Extracorporeal Membrane Oxygenation.
Chang, MJ; Hahn, J; Jang, JY; Kang, S; Kim, D; Lee, JY; Min, KL; Wi, J; Yang, S, 2020
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" Clavulanic acid at a concentration of 10 mg/l bound to PBP 2 by greater than 50% in all strains, and when combined with cefpirome, the density of PBP 2a was also reduced but not completely abolished."( Activity of cefpirome combined with beta-lactamase inhibitors and affinity for the penicillin-binding proteins of methicillin-resistant Staphylococcus aureus.
Griggs, DJ; Piddock, LJ; Traynor, EA, 1992
)
0.28
"The in-vitro activity of cefpirome and ceftazidime when combined with aminoglycosides (gentamicin, amikacin, and tobramycin) in the presence and in the absence of rifampicin was evaluated against 32 isolates of Pseudomonas aeruginosa by two methods."( The effect of rifampicin on the in-vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosa.
Baltch, AL; Hammer, MC; Ritz, WJ; Smith, RP; Valdes, JM, 1990
)
0.28
"Treatment of disseminated Pseudomonas aeruginosa infection in leukopenic mice was evaluated using cefpirome alone and in combination with gentamicin and/or rifampin."( Comparative therapy with cefpirome alone and in combination with rifampin and/or gentamicin against a disseminated Pseudomonas aeruginosa infection in leukopenic mice.
Baltch, AL; Franke, M; Michelsen, P; Ritz, WJ; Singh, J; Smith, RP; Valdes, JM; Williams, S, 1990
)
0.28
"Cefpirome, a so-called fourth-generation cephalosporin, was tested alone and in combination with the sulfone beta-lactamase inhibitor, tazobactam, against 63 members of the Bacteroides fragilis group."( Antimicrobial spectrum of cefpirome combined with tazobactam against the Bacteroides fragilis group.
Barrett, MS; Croco, JL; Erwin, ME; Jones, RN; Novick, WJ,
)
0.13
"In vitro susceptibility studies of cefpirome versus cefotaxime, ceftazidime, imipenem, and piperacillin alone and in combination with tobramycin were performed against 153 clinical isolates of Pseudomonas aeruginosa from four medical centers."( In vitro comparison of cefpirome and four other beta-lactam antibiotics alone and in combination with tobramycin against clinical isolates of Pseudomonas aeruginosa.
Bale, M; Cabezudo, I; Pfaller, M; Wenzel, R,
)
0.13
" A relatively high frequency of synergy was observed when cefpirome was combined with aminoglycosides against both Gram-positive and Gram-negative bacteria."( Beta-lactamase stability and antibacterial activity of cefpirome alone and in combination with other antibiotics.
Bakhtiar, M; Selwyn, S, 1989
)
0.28
" This study is a primary estimation of activity of cefpirome combined with other agents."( [In vitro antibacterial activity of cefpirome in combination with 4 aminoglycosides and 2 fluoroquinolones].
Bryskier, A; Croize, J; Le Noc, D; Le Noc, P, 1988
)
0.27
" The aim of the present study was to evaluate the in vitro bactericidal activity of the new broad spectrum cephalosporins cefepime (FEP) and cefpirome (CPO) alone or in combination with amikacin (AKN), gentamicin (GTN) or ciprofloxacin (CIP) against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacter cloacae producing a derepressed cephalosporinase."( [Kinetics of bactericidal activity of cefepime and cefpirome alone or combined with gentamicin, amikacin or ciprofloxacin against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacter cloacae hyperproductive in cephalosporinase].
Elkhaïli, H; Jehl, F; Kamili, N; Linger, L; Monteil, H; Pompei, D, 1996
)
0.29
" combined with aminoglycosides gentamicin, tobramycin, netilmicin and amikacin."( [Synergic effect of a teicoplanin and cefpirome combination with aminoglucosides on enterococci. Therapeutic importance].
Gutiérrez Fernández, J; Hoyos López, A; Piédrola Angulo, G, 1995
)
0.29
" The 8 h SBTs for dosing schedule containing meropenem combined with amikacin were 1:4 and 1:16 after 30 min short infusion and continuous infusion respectively."( [In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model].
Elkhaïli, H; Jehl, F; Levêque, D; Linger, L; Monteil, H; Niedergang, S; Peter, JD; Pompei, D; Salmon, J; Salmon, Y; Thierry, RC, 1997
)
0.3
"125 x MIC) combined with vancomycin (0."( In-vitro bactericidal activity of cefpirome and cefamandole in combination with glycopeptides against methicillin-resistant Staphylococcus aureus.
Bergeret, M; Raymond, J, 1999
)
0.3

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of cefpirome in rats and dogs after both routes of administration was almost identical when calculated either by the AUC or the urinary recovery rates."( Pharmacokinetics of cefpirome administered intravenously or intramuscularly to rats and dogs.
Isert, D; Klesel, N; Limbert, M; Markus, A; Schrinner, E; Seibert, G, 1992
)
0.28
" The bioavailability after intraperitoneal administration was 84%."( Single-dose pharmacokinetics of cefpirome in patients receiving hemodialysis and in patients treated by continuous ambulatory peritoneal dialysis.
Lameire, N; Lehr, KH; Malerczyk, V; Ringoir, S; Rosenkranz, B; Veys, N, 1993
)
0.29
" The drug can be administered by intravenous or intramuscular injection, but is not well absorbed after oral administration."( Cefpirome clinical pharmacokinetics.
Nix, DE; Strenkoski, LC, 1993
)
0.29
" Because of the obvious drawbacks of drug delivery by injection, the development of alternatives with enhanced oral bioavailability is receiving much attention in pharmaceutical research."( In-vitro and in-vivo studies of cefpirom using bile salts as absorption enhancers.
Bretschneider, B; Härtl, A; Mrestani, Y; Neubert, RH, 2003
)
0.32
"The utilization of the membrane transport protein PEPT1 as a drug delivery system is a promising strategy to enhance the oral bioavailability of drugs."( Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I, 2005
)
0.33
"01) and a very low bioavailability (AUC=524+/-403 microg min/ml)."( Influence of absorption enhancers on the pharmacokinetic properties of non-oral beta-lactam-cefpirom using the rabbit (Chinchilla) in vivo model.
Härtl, A; Mrestani, Y; Neubert, RH, 2006
)
0.33
" Very low bioavailability (2."( Microemulsion and mixed micelle for oral administration as new drug formulations for highly hydrophilic drugs.
Behbood, L; Härtl, A; Mrestani, Y; Neubert, RH, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" As a conclusion, it is necessary to consider the adequate administration and dosage for patients with renal impairment to prevent side effects caused by the maintenance of cefpirome in serum over a long time."( [Pharmacokinetics of cefpirome (CPR) in patients with impaired renal function].
Ogata, Y; Saruta, T; Suzuki, H, 1991
)
0.28
" CPR was administered to 6 patients with bronchopneumonia, a patient with pneumonia, a patient with tonsillitis, 2 patients with acute pharyngitis and a patient with suppurative parotitis at daily dosage levels ranging 55."( [Clinical evaluation of cefpirome in children].
Higashi, H; Ito, S; Mayumi, M; Mikawa, H, 1991
)
0.28
"9%), the vehicle, and 50, 200 or 800/400 mg/kg/d (the highest dosage had to be lowered after the first week due to acute drug intolerance)."( Chronic intravenous toxicity of the new antibiotic cefpirome in monkeys.
Engelbart, K; Horstmann, G, 1990
)
0.28
" In the 6-week-old rats dosed subcutaneously, vocalization, writhing and cutaneous changes at the injection site (dark reddening or blackening, swelling, exfoliation, depilation, induration) were also observed."( [Acute toxicity study of cefpirome sulfate in mice and rats].
Abe, S; Inazu, M; Kobayashi, T; Omosu, M; Oshima, K; Satoh, R; Wada, N, 1990
)
0.28
" This study suggests that a twice daily dosage may be sufficient to treat tissue infections with susceptible pathogens."( Pharmacokinetics and tissue penetration of cefpirome, a new cephalosporin.
Andrews, JM; Ashby, JP; Hillman, G; Kavi, J; Wise, R, 1988
)
0.27
" A general twice daily dosing will be recommended for the treatment of infections."( Dose linearity testing of intravenous cefpirome (HR 810), a novel cephalosporin derivate.
Hajdú, P; Klesel, N; Maass, L; Malerczyk, V; Seeger, K; Verho, M,
)
0.39
") no accumulation of the serum levels could be detected with this dosage regimen."( Single and multiple dose pharmacokinetics of intravenous cefpirome (HR 810), a novel cephalosporin derivative.
Hajdú, P; Klesel, N; Maass, L; Malerczyk, V; Rangoonwala, R; Verho, M,
)
0.37
" After treating infected rabbits for 4 days with various dosing regimens, resistant strains were only detected in those animals in which the time that the serum concentration exceeded the MIC was less than half of the dosing interval."( Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa.
Carbon, C; Fantin, B; Farinotti, R; Thabaut, A, 1994
)
0.29
"Cefpirome is eliminated primarily by renal excretion, compelling dosage reduction in kidney failure."( Single-dose pharmacokinetics of cefpirome in patients receiving hemodialysis and in patients treated by continuous ambulatory peritoneal dialysis.
Lameire, N; Lehr, KH; Malerczyk, V; Ringoir, S; Rosenkranz, B; Veys, N, 1993
)
0.29
" When cefpirome is administered at a dosage of 2g every 12 hours to patients without renal insufficiency [creatinine clearance 70 ml/min (4."( Cefpirome clinical pharmacokinetics.
Nix, DE; Strenkoski, LC, 1993
)
0.29
" These pharmacodynamic characteristics suggest that the goal of optimal dosing regimens for cefpirome is to provide serum levels above the MIC of infecting pathogens for most of the dosing interval."( The pharmacokinetics of cefpirome--rationale for a twelve-hour dosing regimen.
Craig, WA, 1993
)
0.29
" In the LRTI trials 199 patients received cefpirome 1 g bid and in 653 patients it was dosed 2 g bid."( Cefpirome: efficacy in the treatment of urinary and respiratory tract infections and safety profile.
Norrby, SR, 1993
)
0.29
" The higher dosage regimen produced superior bacteriological clearance rates and is therefore preferable in patients with severe septicaemia."( Efficacy of cefpirome in the treatment of septicaemia.
Geddes, AM; Norrby, SR, 1993
)
0.29
" Higher levels are likely to be achieved with multiple dosing and in the presence of inflamed meninges."( Diffusion of 3-quaternary ammonium cephem antibiotics into cerebrospinal fluid of patients with bacterial meningitis.
Modai, J, 1996
)
0.29
" These data show synergistic bactericidal activity of both new extended cephalosporins combined with AKN, GTN or CIP at concentrations achievable in biological fluid with adaptative dosage regimen."( [Kinetics of bactericidal activity of cefepime and cefpirome alone or combined with gentamicin, amikacin or ciprofloxacin against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacter cloacae hyperproductive in cephalosporinase].
Elkhaïli, H; Jehl, F; Kamili, N; Linger, L; Monteil, H; Pompei, D, 1996
)
0.29
"Cefpirome is a cephalosporin eliminated primarily by kidneys that requires dosage reduction in patients with renal failure."( Multiple-dose pharmacokinetics of cefpirome in long-term hemodialysis with high-flux membranes.
Atteneder, M; Breyer, S; Burgmann, H; Elmenyawi, I; Georgopoulos, A; Graninger, W; Hollenstein, U; Hörl, WH; Mayer, G; Putz, D; Rosenkranz, AR; Schmaldienst, S; Thalhammer, F, 1996
)
0.29
" This novel information may be useful for the rational development of dosage schedules and may improve predictions regarding therapeutic outcome."( Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans.
Agneter, E; Burgdorff, T; Eichler, HG; Georgopoulos, A; Haag, O; Jansen, B; Müller, M; Pehamberger, H; Stanek, G; Weninger, W, 1996
)
0.29
" For the six dosage regimens used in this study, the killing activities were similar and resulted in at least 4 log decrease at 6 h after drug exposure."( [In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model].
Elkhaïli, H; Jehl, F; Levêque, D; Linger, L; Monteil, H; Niedergang, S; Peter, JD; Pompei, D; Salmon, J; Salmon, Y; Thierry, RC, 1997
)
0.3
" aeruginosa, the CPO-AG combination is bactericidal at concentrations achievable with standard dosing regimens in man."( [Evaluation of bactericidal activity of cefpirome-aminoglycoside combination against Pseudomonas aeruginosa strains with intermediate sensitivity to cefpirome and in various phenotypes of beta-lactam resistance].
Canis, F; Cavallo, JD; Husson, MO, 1997
)
0.3
"In order to make informed dosage recommendations for patients receiving artificial renal support, cefpirome loss from human blood has been quantified using in vitro models of continuous haemofiltration and haemodiafiltration."( Use of in vitro models of haemofiltration and haemodiafiltration to estimate dosage regimens for critically ill patients prescribed cefpirome.
Davies, JG; Kingswood, C; Olliff, CJ; Phillips, GJ; Street, M, 1998
)
0.3
"The information generated can be used to estimate a dosing regimen for intensive care patients prescribed cefpirome and receiving continuous renal replacement therapy."( Use of in vitro models of haemofiltration and haemodiafiltration to estimate dosage regimens for critically ill patients prescribed cefpirome.
Davies, JG; Kingswood, C; Olliff, CJ; Phillips, GJ; Street, M, 1998
)
0.3
"No major pharmacokinetic modification was noted when cefpirome was given to trauma patients with posttraumatic SIRS without significant organ failure, indicating that no dosage adjustment seems required in this population."( Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome.
Edouard, AR; Incagnoli, P; Jacolot, A; Mimoz, O; Petitjean, O; Samii, K; Tod, M, 1999
)
0.3
" A total of 42 patients, all hospitalized for cataract extraction, received a dosage of 1 g or 2 g of cefpirome by iv infusion 1, 2 or 6 h preoperatively."( Penetration of cefpirome into the anterior chamber of the human eye after intravenous application.
Alzner, E; Egger, SF; Elmenyawi, I; Georgopoulos, A; Georgopoulos, M; Grabner, G; Huber-Spitzy, V, 2000
)
0.31
"The sieving coefficient (64%) indicates that a substantial fraction of the drug is not filtered; clearance by pathways other than CVVH mounted to 50% of the total clearance and increased on day 2, indicating that the dosing schedule used is appropriate for this setting."( Pharmacokinetics of cefpirome in critically ill patients with renal failure treated by continuous veno-venous hemofiltration.
Fijen, JW; Ligtenberg, JJ; Möller, AV; Spanjersberg, R; Stegeman, CA; Tulleken, JE; Van de Merbel, NC; Van der Werf, TS; Zijlstra, JG, 1999
)
0.3
" The administration dosage of CPR was 2 to 4 gram per day administered by drip infusion or intravenous infusion."( [Clinical efficacy of cefpirome sulfate against Bacteroides species, Prevotella species and Porphyromonas species. Society of Anaerobic Bacterial Infections in the fields of obstetrics and gynecology in Gifu].
Arahori, K; Furui, K; Furuta, N; Hashiyama, T; Hattori, S; Hayasaki, Y; Hirose, R; Hua, YX; Ito, M; Iwasa, S; Izumi, K; Kawazoe, K; Mikamo, H; Morishita, S; Nakagawa, M; Nomura, M; Ohnishi, N; Sakakibara, K; Sato, Y; Shiraki, S; Sugiyama, M; Tamaya, T; Tsukahara, Y; Watanabe, K; Yamada, Y, 2000
)
0.31
"Although susceptible organisms will usually be covered sufficiently with standard dosing regimens, soft tissue infections with bacteria that have MIC values of 2 to 8 may profit from continuous application."( Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers.
Brunner, M; Delacher, S; Eichler, HG; Erovic, B; Hollenstein, U; Mayer, BX; Müller, M, 2000
)
0.31
"Cefpirome is a new semisynthetic cephalosporin, primarily eliminated by the kidneys, that requires dosage adjustment in patients with kidney failure."( Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval.
Banyai, M; El-Menyawi, I; Heinz, G; Siostrzonek, P; Thalhammer, F; Traunmüller, F, 2000
)
0.31
" All patients received a dosage of 2 g cefpirome every 8 hours after starting the hemofiltration with high-flux polysulfone membranes."( Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval.
Banyai, M; El-Menyawi, I; Heinz, G; Siostrzonek, P; Thalhammer, F; Traunmüller, F, 2000
)
0.31
"8 microg/mL at the end of the dosing interval."( Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval.
Banyai, M; El-Menyawi, I; Heinz, G; Siostrzonek, P; Thalhammer, F; Traunmüller, F, 2000
)
0.31
" However, this dosage may be insufficient during CVVH for intermediate resistant strains of Pseudomonas aeruginosa."( Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval.
Banyai, M; El-Menyawi, I; Heinz, G; Siostrzonek, P; Thalhammer, F; Traunmüller, F, 2000
)
0.31
" To use the pharmacokinetic model to simulate alternate dosing regimens and identify those that predict sustained levels."( Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing.
Fraenkel, D; Lipman, J; Rickard, CM; Wallis, SC, 2001
)
0.31
" Timed blood samples were taken prior to and during two dosing intervals."( Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing.
Fraenkel, D; Lipman, J; Rickard, CM; Wallis, SC, 2001
)
0.31
" Pharmacokinetic simulation predicted that more frequent bolus dosing, increased doses and continuous infusions would result in concentrations greater than 4 mg/l for over 60% of the dosing interval for all patients."( Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing.
Fraenkel, D; Lipman, J; Rickard, CM; Wallis, SC, 2001
)
0.31
" Direct measurement of interstitial concentrations of antimicrobial agents in human lung tissue would allow for a more informed approach to appropriate dosing of antimicrobial agents, but until now this was beyond technical reach."( Closed-chest microdialysis to measure antibiotic penetration into human lung tissue.
Frossard, M; Herkner, H; Joukhadar, C; Klein, N; Kreischitz, N; Lackner, E; Mayer, BX; Müller, M; Müller, MR, 2002
)
0.31
"Standard dosage recommendations for beta-lactam antibiotics can result in very low drug levels in intensive care (IC) patients without renal dysfunction."( Cefepime versus cefpirome: the importance of creatinine clearance.
Boots, RJ; Lipman, J; Wallis, SC, 2003
)
0.32
" This tendency inverse correlated to decreasing dosage of PCs."( [The trend and susceptibility to antibacterial agents of enterococcus species from urinary tract infections].
Hoshinaga, K; Ishikawa, K; Miyakawa, S; Naide, Y; Shiroki, R; Tanaka, T, 2004
)
0.32
" By consideration of a dosing interval of 8 h, the values for the time above MIC (T > MIC) in tissue were greater than 60% for pathogens for which the MIC was ( Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients.
Delle-Karth, G; Georgopoulos, A; Joukhadar, C; Marsik, C; Mayer-Helm, BX; Müller, M; Sauermann, R; Steiner, I; Zeitlinger, M, 2005
)
0.33
" In addition, the pharmacokinetics and optimal dosing regimen of cefpirome during neutropenia were investigated."( Cefpirome as empirical treatment for febrile neutropenia in patients with hematologic malignancies.
Huijgens, PC; Simoons-Smit, AM; Swart, EL; Timmers, GJ; van Vuurden, DG, 2005
)
0.33
" Also, an appropriate dosage regimen was calculated."( Disposition kinetics and urinary excretion of cefpirome after intravenous injection in buffalo calves.
Dumka, VK; Rajput, N; Sandhu, HS, 2007
)
0.34
" Concentration-time profiles were evaluated by the probability of achieving free-drug concentrations above the MIC for more than 65% of dosing interval."( Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria.
Kirkpatrick, CMJ; Lipman, J; Roos, JF, 2007
)
0.34
"Knowledge on the elimination of antibiotics by extracorporeal hemofiltration is a prerequisite for appropriate antimicrobial dosing in patients with renal failure."( Daptomycin elimination by CVVH in vitro: evaluation of factors influencing sieving and membrane adsorption.
Steiner, I; Wagner, CC; Zeitlinger, M, 2009
)
0.35
" adipose tissue met the efficacy breakpoint (percentage of the time that free drug concentrations remained above the MIC) for at least 40% of the 8-h dosing interval for organisms with a MIC of 2 mg/liter."( Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
Barbour, A; Derendorf, H; Grant, M; Murthy, B; Sabarinath, SN; Schmidt, S; Seubert, C; Skee, D, 2009
)
0.35
" Under steady-state conditions, the median concentrations of cefpirome in plasma, unaffected lung and infected lung exceeded the MICs of the majority of relevant bacteria over the entire dosing interval of up to 12 h after intravenous administration of a dose of 30 mg/kg total body weight."( High extracellular levels of cefpirome in unaffected and infected lung tissue of patients.
Dittrich, P; Graninger, W; Joukhadar, C; Kugler, SA; Lindenmann, J; Maier, A; Matzi, V; Porubsky, C; Smolle-Jüttner, FM, 2011
)
0.37
" Population PK and Monte Carlo simulations were performed using NONMEM and S-ADAPT and a duration of an unbound plasma concentration above the MIC ≥ 65% of the dosing interval as a pharmacodynamic target."( Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.
Bulitta, JB; Holzgrabe, U; Kinzig, M; Landersdorfer, CB; Sörgel, F; Stephan, U, 2011
)
0.37
" Consequently, the dosing of antibiotics should be supported by PK concepts, including data derived from studies of the PK of ICU patients and therapeutic drug monitoring."( Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J; Póvoa, P, 2011
)
0.37
" Given a range of built-in features and its inherent flexibility to customization, the model can be used to study a variety of pharmacokinetic and pharmacodynamic problems such as the effects of inter-individual differences and disease-states on drug pharmacokinetics and pharmacodynamics, dosing optimization, and inter-species scaling."( BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems.
Graf, JF; Scholz, BJ; Zavodszky, MI, 2012
)
0.38
"To obtain the optimal dosage regimen in patients receiving extracorporeal membrane oxygenation (ECMO), we developed a population pharmacokinetics model for cefpirome and performed pharmacodynamic analyses."( Dose Optimization of Cefpirome Based on Population Pharmacokinetics and Target Attainment during Extracorporeal Membrane Oxygenation.
Chang, MJ; Hahn, J; Jang, JY; Kang, S; Kim, D; Lee, JY; Min, KL; Wi, J; Yang, S, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
cyclopentapyridine
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency51.21130.141337.9142100.0000AID1490; AID2701; AID2707
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624170
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency28.18380.354828.065989.1251AID504847
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency31.62280.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 15 member 1Homo sapiens (human)Ki30,000.00000.18003.39339.8000AID238858; AID681115
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki9,500.00003.00006.47788.5000AID681114
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase Citrobacter gilleniiKm304.000010.000010.000010.0000AID285442
Beta-lactamase Aeromonas caviaeKm48.00007.00007.00007.0000AID374363
Beta-lactamase Shouchella clausiiKm136.00000.01003.00506.0000AID373209
Beta-lactamase Acinetobacter baumanniiKm700.00003.00005.66679.0000AID567279
Metallo-beta-lactamase VIM-11 Pseudomonas aeruginosaKm183.00004.50007.00009.4000AID520385
Metallo-beta-lactamase VIM-2Pseudomonas aeruginosaKm171.00005.50007.87509.9000AID520386
Beta-lactamase Aeromonas allosaccharophilaKm1,500.00001.50006.300010.0000AID584846
Beta-lactamase Acinetobacter baumanniiKm1,700.00006.00007.666710.0000AID567280
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Km304.000010.000010.000010.0000AID285442
Beta-lactamase Salmonella enterica subsp. enterica serovar WesthamptonKm125.000010.000010.000010.0000AID556340
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (249)

Assay IDTitleYearJournalArticle
AID373051Antimicrobial activity against Bacillus clausii ATCC 21537 by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID584847Ratio of Kcat to Km for Aeromonas allosaccharophila AL-1 beta-lactamase PER62010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID228704In vitro dose required for anticholinergic activity in isolated guinea pig trachea1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID164867Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Pseudomonas aeruginosa 90272000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID206460In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Staphylococcus aureus (3849)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID495903Antimicrobial activity in Escherichia coli DIH-1 expressing beta-lactamase VIM-19 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID495904Antimicrobial activity in Klebsiella pneumoniae DIH-2 clinical isolate expressing beta-lactamase VIM-19 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID564531Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid with entire blaAmpC gene by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID561813fAUC in adipose tissue of healthy human at 2 g, iv up to 10 mins by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID252617Mean lysis diameter of Enterobacter aerogenes EA289 with D113A mutation by standard disk diffusion method on MH agar2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Beta-lactam screening by specific residues of the OmpF eyelet.
AID522386Antimicrobial activity against Escherichia coli NI540 carrying cloned class C beta-lactamase TRU-1 gene2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID95736Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Klebsiella oxytoca 1082 E2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID561815Ratio of fAUC in muscle to fAUC in plasma of healthy human at 2 g, iv up to 8 hrs by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID543419Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID495655Antimicrobial activity against Pseudomonas aeruginosa 51170 expressing beta-lactamase BEL-1 by solid agar dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID584835Antimicrobial activity against Aeromonas allosaccharophila AL-1 expressing beta-lactamase PER6 by agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID520383Antimicrobial activity Escherichia coli DH5alpha expressing metallo-beta-lactamase VIM-11 by agar macrodilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID373052Antimicrobial activity against Escherichia coli DH10B carrying pJIM2246 expressing Bacillus clausii NR beta-lactamase BCL1 by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID495656Antimicrobial activity against Escherichia coli TOP10 expressing recombinant beta-lactamase BEL-2 by solid agar dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID520388Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 metallo-beta lactamase VIM-22008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID584846Activity at Aeromonas allosaccharophila AL-1 beta-lactamase PER62010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID68060Antibacterial activity against Enterococcus faecium1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID681115TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in Caco-2 cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID70595Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Escherichia coli 1507E2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID495905Antimicrobial activity in Escherichia coli TOP10 hourbouring recombinant plasmid VIM-19 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID67911In vitro antibacterial activity against clinical isolates Enterococcus faecalis was determined1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID660265Antimicrobial activity against wild type Escherichia coli expressing AcrAB-TolC efflux pump2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID520385Activity at Pseudomonas aeruginosa M5109 metallo-beta-lactamase VIM-11 by spectrometry2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID561829fAUC in muscle of healthy human at 2 g, iv up to 10 mins by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID68181Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Enterobacter cloacae 13212000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID210362In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Streptococcus pneumoniae (4629)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID374363Activity of Aeromonas caviae A324R metallo-beta-lactamase IMP-19 expressed in Escherichia coli DH5alpha by computerized microacidimetric method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID559922Antibacterial activity against Escherichia coli TOP10 harboring recombinant plasmid RTG4-V49 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID562812Antimicrobial activity against Escherichia coli DH5[alpha]2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID285442Activity of Citrobacter gillenii CIP 106783 Beta-lactamase GIL1 expressed in Escherichia coli DH10B2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID584836Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER6 by agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID373207Antimicrobial activity against Bacillus clausii ATCC 21536 by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID559918Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase RTG4 gene by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID561819Ratio of fAUC in adipose tissue to fAUC in plasma of healthy human at 2 g, iv up to 8 hrs by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID564529Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID567280Activity of Acinetobacter baumannii ADC-11 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID561812fAUC in adipose tissue of healthy human at 2 g, iv up to 15 mins by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID209443Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Streptococcus pyogenes A772000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID210364In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Streptococcus pneumoniae (4635)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID373211Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3) relative to benzyl-penicillin2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID208612In vitro antibacterial activity against clinical isolates Ampicillin-insensitive Streptococcus pneumoniae was determined1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID205572Antibacterial activity was determined against Staphylococcus epidermidis ATCC 12228 (Gram-positive)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID520386Activity at Pseudomonas aeruginosa COL-1 metallo-beta lactamase VIM-2 by spectrometry2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID562811Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID556340Activity of Salmonella enterica serotype Westhampton beta-lactamase CTX-M-532009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID567287Antimicrobial activity against Acinetobacter baumannii beta-lactamase by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID113436Antibacterial activity was determined against Escherichia coli 29 at a challenge dose of 1.35*10e6 (cells/mouse) administered subcutaneously1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID208622In vitro antibacterial activity against clinical isolates Ampicillin-insensitive Streptococcus pneumoniae was determined1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID373210Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3)2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID69932Antibacterial activity was determined against Escherichia coli NIHJ JC-2 (Gram-negative)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID69605Antibacterial activity against Escherichia coli EC141990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID373209Activity of Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3)2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID95719Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Klebsiella aerogenes 1522 E2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID209467In vitro antibacterial activity against the gram-positive bacteria, erythromycin resistant Streptococcus pyogenes1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID584838Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER2 by agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID495657Antimicrobial activity against Escherichia coli TOP10 expressing recombinant beta-lactamase BEL-1 by solid agar dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID95913Antibacterial activity against Klebsiella pneumoniae 1082E1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID373053Antimicrobial activity against Escherichia coli DH10B by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID96071Antibacterial activity was determined against Klebsiella pneumoniae NCTC 9632 (Gram-negative)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID562220Antimicrobial activity against Desulfovibrio sp. by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID561827Ratio of fAUC in muscle to fAUC in plasma of healthy human at 2 g, iv up to 10 mins by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID560117Antibacterial activity against Escherichia coli TOP10 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID560115Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase RTG3 gene by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID285441Antimicrobial activity against Escherichia coli DH10B after 18 hrs by disk diffusion method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID285440Antimicrobial activity against Escherichia coli DH10B expressing GIL1 after 18 hrs by disk diffusion method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID522392Ratio of Kcat Km for Aeromonas enteropelogenes Beta-lactamase TRU12010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID520389Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 metallo-beta lactamase VIM-2 over Kcat to Km for Pseudomonas aeruginosa M5109 metallo-beta-lactamase VIM-112008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID561816fAUC in muscle of healthy human at 2 g, iv up to 8 hrs by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID562814Antimicrobial activity against Escherichia coli J53 in presence of beta-lactamase inhibitor clavulanic acid2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID567281Ratio of Kcat to Km for Acinetobacter baumannii ADC-33 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID206866Antibacterial activity against penicillin G susceptible Staphylococcus aureus1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID562815Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases in presence of beta-lactamase inhibitor clavulanic acid2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID164392Antibacterial activity was determined against Pseudomonas aeruginosa ATCC 10145 (Gram-negative)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID67569In vivo efficacy was determined against Enterococcus faecalis C 00631995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID208629In vitro antibacterial activity against clinical isolates Ampicillin-insensitive Streptococcus pneumoniae was determined1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID68012Antibacterial activity against Enterobacter cloacae EB51990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID560133Ratio of Kcat to Km for recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID564525Antimicrobial activity against Acinetobacter baumannii CIP70.10 by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID70597Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Escherichia coli DC 22000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID205950Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Staphylococcus aureus 5032000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID164738Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Pseudomonas aeruginosa 17712000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID520384Antimicrobial activity Escherichia coli DH5alpha expressing beta lactamase VIM-2 by agar macrodilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID543427Antimicrobial activity against Escherichia coli XL-1 Blue harboring plasmid CL1920 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID495909Antimicrobial activity in Escherichia coli J53 transconjugate with Escherichia coli DIH-1 expressing natural plasmid containing beta-lactamase VIM-192010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID373204Antimicrobial activity against Bacillus clausii SIN by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID559920Antibacterial activity against Escherichia coli TOP10 harboring recombinant plasmid RTG4-S69 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID95918Antibacterial activity against Klebsiella pneumoniae X261990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID498872Antimicrobial activity against Acinetobacter baumannii B9 containing carbapenemase blaOXA-23 gene assessed as growth inhibition by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.
AID584839Antimicrobial activity against Escherichia coli DH10B by agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID561817fAUC in plasma of healthy human at 2 g, iv up to 8 hrs by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID113443Antibacterial activity was determined against Staphylococcus aureus Smith at a challenge dose of 1.32*10e7 (cells/mouse) administered subcutaneously (value in parentheses indicates 95% CL)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID567279Activity of Acinetobacter baumannii ADC-33 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID564526Antimicrobial activity against Acinetobacter baumannii AYE expressing VEB-1 gene by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID560134Activity of recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 assessed as Ratio of Kcat to Km by nitrocefin hydrolysis assay relative to benzylpenicillin2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID210366In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Streptococcus pneumoniae (3272)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID567282Ratio of Kcat to Km for Acinetobacter baumannii ADC-11 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID19128Terminal half life in Rhesus monkeys at the dose of 30 mg/kg.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID373058Antimicrobial activity against Escherichia coli DH10B carrying pJIM2246 expressing Bacillus clausii NR beta-lactamase BCL1 by agar-dilution technique in presence of beta-lactamase inhibitor clavulanic acid2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID495654Antimicrobial activity against Pseudomonas aeruginosa 531 expressing beta-lactamase BEL-2 by solid agar dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID560131Activity of recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID252634Bacterial susceptibility induced by D113 mutation in Escherichia coli OmpF2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Beta-lactam screening by specific residues of the OmpF eyelet.
AID205382Antibacterial activity was determined against Serratia marcescens ATCC 12648 (Gram-negative)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID210368In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Streptococcus pneumoniae (3512)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID70598Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Escherichia coli O 552000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID522388Activity of Aeromonas enteropelogenes Beta-lactamase TRU12010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID522384Antimicrobial activity against Aeromonas enteropelogenes ATCC 49803 producing endogenous class C beta-lactamase TRU-12010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID564527Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID520382Antimicrobial activity Escherichia coli DH5alpha harboring bacteriophage T4 plasmid alpha omega by agar macrodilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID252635Bacterial susceptibility induced by D121 mutation in Escherichia coli OmpF2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Beta-lactam screening by specific residues of the OmpF eyelet.
AID373061Antimicrobial activity against Escherichia coli BL21(DE3) by agar-dilution technique in presence of beta-lactamase inhibitor clavulanic acid2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID374362Ratio of Kcat to Km of Aeromonas caviae A324R metallo-beta-lactamase IMP-19 expressed in Escherichia coli DH5alpha by computerized microacidimetric method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID207480Antibacterial activity was determined against Methicillin-resistant Staphylococcus aureus (MRSA) 5038 (Gram-positive)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID68010Antibacterial activity against Enterobacter cloacae 265A1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID528606Activity of Escherichia coli 2138 beta-lactamase KPC-2 by spectrophotometry2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID562223Antimicrobial activity against Desulfovibrio desulfuricans MB by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID200862Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Salmonella Typhimurium2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID495658Antimicrobial activity against Escherichia coli TOP10 by solid agar dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID206644In vitro antibacterial activity against clinical isolates methicillin-resistant Staphylococcus aureus was determined1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID564536Antimicrobial activity against Escherichia coli TOP10 harboring pTOPO plasmid by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID567283Ratio of Kcat to Km for Acinetobacter baumannii ADC-33 beta-lactamase to Kcat to Km for Acinetobacter baumannii ADC-11 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID206783In vitro antibacterial activity against clinical isolates methicillin-resistant Staphylococcus aureus was determined1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID564534Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid carrying entire blaAmpC gene with alanine residue deletion at 215 position and R210P substitution by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID67077Antibacterial activity was determined against Enterococcus faecalis ATCC 21212 (Gram-positive)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID660261Ratio of MIC for wild type Escherichia coli JC7623 to MIC for acrAB-deficient Escherichia coli JZM1202012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID564524Antimicrobial activity against Acinetobacter baumannii KI by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID528608Ratio of Kcat to Km for Escherichia coli 2138 beta-lactamase KPC-2 by spectrophotometry2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID207482Antibacterial activity was determined against Staphylococcus aureus FDA 209P (Gram-positive)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID252619Mean lysis diameter was measured against Enterobacter aerogenes EA289 with D121A mutation by standard disk diffusion method on MH agar2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Beta-lactam screening by specific residues of the OmpF eyelet.
AID520387Ratio of Kcat to Km for Pseudomonas aeruginosa M5109 metallo-beta-lactamase VIM-112008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID495908Antimicrobial activity in Escherichia coli TOP10 harbouring recombinant plasmid VIM-1-N215K by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID562222Antimicrobial activity against Desulfovibrio desulfuricans Essex 6 by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID373055Antimicrobial activity against Escherichia coli BL21(DE3) by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID70596Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Escherichia coli DC 02000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID210363In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Streptococcus pneumoniae (4630)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID67904In vitro antibacterial activity against clinical isolates Enterococcus faecalis was determined1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID561814Ratio of fAUC in adipose tissue to fAUC in plasma of healthy human at 2 g, iv up to 15 mins by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID76915In vitro relative anticholinergic potential in isolated guinea pig trachea1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID206639In vitro antibacterial activity against clinical isolates methicillin-resistant Staphylococcus aureus was determined1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID1706551Protection against Staphylococcus aureus Smith infected in sc dosed mouse administered 1 hr post infection and measured at 7 days post infection by Litchfield-Wilcoxon method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Hydroxypyridinone-Based Iron Chelators with Broad-Ranging Biological Activities.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID373217Ratio of Kcat for Bacillus clausii NR beta-lactamase BCL1 to Kcat for Bacillus cereus beta lactamase BcI2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID210248Antibacterial activity against Streptococcus pyogenes1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID205951Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Staphylococcus aureus SG5112000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID206461In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Staphylococcus aureus (663E)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID495907Antimicrobial activity in Escherichia coli TOP10 strain harbouring recombinant plasmid VIM-1 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID210367In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Streptococcus pneumoniae (3273)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID584837Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER1 by agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID564532Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid with entire blaAmpC gene with alanine residue deletion at 215 position by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID543411Antimicrobial activity against Shigella sonnei UIH-1 expressing beta-lactamase CTX-M-64 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID252618Mean lysis diameter of wild type Enterobacter aerogenes EA289 with OmpF by standard disk diffusion method on MH agar2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Beta-lactam screening by specific residues of the OmpF eyelet.
AID205379Antibacterial activity against Serratia marcescens SE31990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID564533Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid carrying entire blaAmpC gene with alanine residue insertion at 215 position by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID495906Antimicrobial activity in Escherichia coli TOP10 hourbouring recombinant plasmid VIM-4 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID495910Antimicrobial activity in Escherichia coli TOP10 strain2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID79506In vitro relative anticholinergic activity in isolated guinea pig trachea1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID567286Antimicrobial activity against Acinetobacter baumannii expressing ESAC beta-lactamase by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID69020In vivo efficacy was determined against Escherichia coli 291995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID210365In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Streptococcus pneumoniae (4636)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID209892Antibacterial activity against Streptococcus pneumoniae1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID164246Antibacterial activity against Pseudomonas aeruginosa X5281990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID562809Antimicrobial activity against Escherichia coli J532009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID285443Ratio of kcat to Km of Citrobacter gillenii CIP 106783 Beta-lactamase GIL1 expressed in Escherichia coli DH10B relative to benzyl-penicillin2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID209441Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Streptococcus pyogenes 8b2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID561810fAUC in plasma of healthy human at 2 g, iv up to 10 mins by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID495911Antimicrobial activity in Escherichia coli J53 strain2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID564535Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid carrying entire blaAmpC gene with alanine residue insertion at 215 position and R210P substitution by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID206456In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Staphylococcus aureus (2619)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID562817Antimicrobial activity against Escherichia coli DH5[alpha] in presence of beta-lactamase inhibitor clavulanic acid2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID562224Antimicrobial activity against Desulfovibrio piger by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID564528Antimicrobial activity against Escherichia coli TOP10 harboring pADC-50 plasmid by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID560128Antimicrobial activity against Acinetobacter baumannii CIP70.10 by disk diffusion method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID562221Antimicrobial activity against Desulfovibrio fairfieldensis by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID164241Antibacterial activity against Pseudomonas aeruginosa PS181990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID67902In vitro antibacterial activity against clinical isolates Enterococcus faecalis was determined1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID561811fAUC in plasma of healthy human at 2 g, iv up to 15 mins by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID373205Antimicrobial activity against Bacillus clausii T by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID206865Antibacterial activity against penicillin G resistance Staphylococcus aureus1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID522385Antimicrobial activity against Aeromonas enteropelogenes M1 hyperproducing beta-lactamase AmpC2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID543415Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 transconjugant by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID164866Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Pseudomonas aeruginosa 1771 M2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID560113Antibacterial activity against Escherichia coli TOP10 harboring recombinant plasmid RTG4-S69-V49 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID373057Antimicrobial activity against Bacillus clausii ATCC 21537 by agar-dilution technique in presence of beta-lactamase inhibitor clavulanic acid2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID373056Antimicrobial activity against Bacillus clausii NR expressing beta-lactamase BCL1 by agar-dilution technique in presence of beta-lactamase inhibitor clavulanic acid2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID373206Antimicrobial activity against Bacillus clausii OC by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID209442Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Streptococcus pyogenes A 3082000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID164737Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Pseudomonas aeruginosa 1592 E2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID562810Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID561824Ratio of fAUC in adipose tissue to fAUC in plasma of healthy human at 2 g, iv up to 10 mins by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID113439Antibacterial activity was determined against MRSA 5120 at a challenge dose of 7.6*10e7 (cells/mouse) administered subcutaneously1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID562813Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID564530Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid with entire blaAmpC gene by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID285439Antimicrobial activity against Citrobacter gillenii CIP 106783 after 18 hrs by disk diffusion method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID205835Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Staphylococcus aureus 2852000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID70951Antibacterial activity against Escherichia coli TEM1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID543423Antimicrobial activity against Escherichia coli XL-1 Blue transconjugant harboring beta-lactamase CTX-M-64 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID113437Antibacterial activity was determined against Enterococcus faecalis C 0063 at a challenge dose of 7.00*10e7 (cells/mouse) administered subcutaneously1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID238858Binding affinity against membrane transport protein PEPT1 in human Caco-2 cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID206457In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Staphylococcus aureus (2672)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID207381In vivo efficacy was determined against Staphylococcus aureus Smith1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID68182Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Enterobacter cloacae P992000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID70599Compound was tested in vitro for its minimum inhibitory concentration by serial 2-fold agar dilution Muller Hinton method against Escherichia coli TEM2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.
AID373054Antimicrobial activity against Escherichia coli BL21(DE3) carrying pET9a expressing Bacillus clausii beta-lactamase BCL1 by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID560125Antimicrobial activity against Acinetobacter baumannii CIP70.10 harboring beta-lactamase RTG3 gene by disk diffusion method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID522387Antimicrobial activity against Escherichia coli TOP102010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID560122Antimicrobial activity against Acinetobacter baumannii CIP70.10 harboring beta-lactamase RTG4 gene by disk diffusion method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID562816Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases in presence of beta-lactamase inhibitor clavulanic acid2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID556341Ratio of Kcat/Km for Salmonella enterica serotype Westhampton beta-lactamase CTX-M-532009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID373208Antimicrobial activity against Bacillus clausii DSM 8716 by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID561818fAUC in adipose tissue of healthy human at 2 g, iv up to 8 hrs by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID560119Antimicrobial activity against Acinetobacter baumannii by disk diffusion method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID206459In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Staphylococcus aureus (3072)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID560132Activity of recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay relative to benzylpenicillin2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID681114TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in SKPT cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID206458In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Staphylococcus aureus (853)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID562818Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases in presence of beta-lactamase inhibitor clavulanic acid2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID252616Mean lysis diameter of porin deficient Enterobacter aerogenes EA289 by standard disk diffusion method on MH agar2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Beta-lactam screening by specific residues of the OmpF eyelet.
AID207379In vivo efficacy was determined against MRSA 51201995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.
AID373060Antimicrobial activity against Escherichia coli BL21(DE3) carrying pET9a expressing Bacillus clausii beta-lactamase BCL1 by agar-dilution technique in presence of beta-lactamase inhibitor clavulanic acid2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID126324Percent of dose in Rhesus monkeys urine at the dose of 30 mg/kg.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID373059Antimicrobial activity against Escherichia coli DH10B by agar-dilution technique in presence of beta-lactamase inhibitor clavulanic acid2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (366)

TimeframeStudies, This Drug (%)All Drugs %
pre-199059 (16.12)18.7374
1990's205 (56.01)18.2507
2000's70 (19.13)29.6817
2010's28 (7.65)24.3611
2020's4 (1.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.63 (24.57)
Research Supply Index6.10 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index27.14 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials45 (11.25%)5.53%
Reviews16 (4.00%)6.00%
Case Studies10 (2.50%)4.05%
Observational0 (0.00%)0.25%
Other329 (82.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]